IVF INVO Fertility, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1417926 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY15.2%
TTM net income YoY82.9%
TTM EPS YoY138.9%
Revenue 3-yr CAGR61.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-72.2%
Net margin-59.9%
FCF margin—
EBITDA margin-64.6%
Returns
ROE-40.5%
ROA-21.6%
ROIC (approx.)-34.7%
Asset turnover0.36x
Leverage & solvency
Liabilities / assets29.4%
Debt / equity0.05x
Current ratio1.00x
Interest coverage-5.06x
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.84M | $6.53M |
| Cost of revenue | $30,571 | $12,201 |
| Gross profit | $6.81M | $6.52M |
| R&D expense | — | $4,880 |
| SG&A expense | $7.69M | $8.07M |
| Operating income | -$7.24M | -$6.63M |
| Interest expense | $1.30M | $1.04M |
| Pretax income | -$5.49M | -$7.60M |
| Income tax | -$150,371 | $140,202 |
| Net income | -$23.32M | -$9.26M |
| EBITDA | -$6.56M | -$5.71M |
| EPS (basic) | -214.64 | -3,782.65 |
| EPS (diluted) | -214.64 | -3,782.65 |
| Weighted avg. shares (diluted) | 117,083 | 2,514 |
| Balance sheet | ||
| Cash & equivalents | $0 | $619,520 |
| Receivables | $217,263 | $113,108 |
| Inventory | $225,253 | $219,764 |
| Current assets | $2.76M | $1.26M |
| PP&E, net | $386,165 | $466,684 |
| Goodwill | $5.88M | $5.88M |
| Intangibles | $1.33M | $3.28M |
| Total assets | $20.22M | $46.08M |
| Current liabilities | $10.33M | $17.87M |
| Short-term debt | $1.27M | $6.34M |
| Long-term debt | $744,725 | $1.13M |
| Total debt | $2.02M | $7.47M |
| Total liabilities | $13.00M | $26.04M |
| Shareholders' equity | $7.22M | $12.58M |
| Net debt | $2.02M | $6.85M |
| Shares outstanding | 119,358 | 3,111 |
| Cash flow statement | ||
| Operating cash flow | -$7.01M | -$2.97M |
| Capital expenditure | $43,412 | $183,703 |
| Free cash flow | -$7.06M | -$3.16M |
| Investing cash flow | -$2.75M | $363,895 |
| Financing cash flow | $11.10M | $3.12M |
| Depreciation & amortization | $677,364 | $919,603 |
| Stock-based compensation | $162,920 | — |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.